The combination of belzutifan plus lenvatinib significantly improved outcomes for patients with clear cell renal cell ...
A large national study in Denmark following nearly 1,900 patients over almost a decade found that a minimally invasive ...
A large national study in Denmark following nearly 1,900 patients over almost a decade has found that a minimally invasive ...
Merck presents positive results from phase 3 LITESPARK-022 trial of Keytruda plus Welireg in certain patients with earlier-stage RCC at 2026 ASCO cancers symposium: Rahway, New Je ...
For Patients With mCRPC, Results With Pluvicto in Real-World Settings Keep Pace With Clinical Trials
Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after one ARPI and delayed chemotherapy.
The global oncology market is projected to nearly triple from $279.98 billion in 2026 to an estimated $748.17 billion by 2035 ...
A large national study in Denmark following nearly 1,900 patients over almost a decade found that a minimally invasive procedure ...
Dedifferentiated liposarcoma lacks effective IGF-1→PPAR-γ adipogenic signaling due to epigenetic silencing of PPAR-γ2, with ...
Arcus Biosciences beat FY25 EPS/revenue estimates as Casdatifan drives upside; $1.01B cash funds Phase 3 into 2H28. Click for my latest analysis of RCUS stock.
Cumberland Pharmaceuticals Inc. ( CPIX) Q4 2025 Earnings Call March 3, 2026 4:30 PM EST Good afternoon, and welcome to Cumberland Pharmaceuticals 2025 Financial Report and Company Update. This call is ...
Merck MRK has a strong foothold in the oncology market, primarily supported by its biggest revenue driver, Keytruda. The ...
Overview of Ac‑225 PSMA therapy, what real patient cases can illustrate about the treatment pathway, and key steps for eligibility review and choosing a center.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results